Literature DB >> 15013125

Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure.

Aun Yeong Chong1, Graham J Caine, Bethan Freestone, Andrew D Blann, Gregory Y H Lip.   

Abstract

OBJECTIVES: The goal of this research was to test the hypothesis that plasma angiopoietin (Ang-1), its soluble receptor tie-2, and Ang-2 levels would be abnormal in patients with acute and chronic congestive heart failure (CHF) when compared with healthy controls.
BACKGROUND: Increased plasma vascular endothelial growth factor (VEGF) in CHF is suggestive of excess angiogenesis-possibly driven by tissue hypoxia. However, other growth factors also have a major role in angiogenesis, such as those of the angiopoietin family (e.g., Ang-1, which exerts its activity via its receptor, tie-2, and Ang-2).
METHODS: We recruited 39 patients with acute CHF (mean age 67 +/- 10 years), 40 patients with chronic CHF (mean age 63 +/- 9 years), and 17 healthy controls (mean age 67 +/- 7 years), all in sinus rhythm. Citrated plasma was analyzed for Ang-1, Ang-2, tie-2, and VEGF by enzyme-linked immunosorbent assay.
RESULTS: Angiopoietin-2 (p < 0.001), tie-2 (p < 0.05), and VEGF (p < 0.05) levels were all higher in acute CHF compared with controls. The Ang-2 levels were higher in acute CHF compared with chronic CHF (p < 0.001), but there were no significant differences in Ang-1 levels between the groups. The principal significant correlations were between Ang-2 and tie-2 (Spearman, r = 0.407; p < 0.0001) and between Ang-2 and ejection fraction (r = -0.241, p = 0.043). Although only marginally raised, levels of VEGF correlated with both Ang-2 (r = 0.468, p < 0.001) and tie-2 (r = 0.569, p < 0.001).
CONCLUSIONS: We have demonstrated abnormal levels of Ang-2 and tie-2, but normal Ang-1, in both CHF patients. These abnormalities may, alongside VEGF, indicate a role for these angiogenic factors in the pathophysiology of CHF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013125     DOI: 10.1016/j.jacc.2003.08.042

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  43 in total

1.  Analysis of serum angiogenic factors in a young multiple myeloma patient with high-output cardiac failure.

Authors:  Kazunari Sasaki; Kouhei Yamashita; Takashi Miyoshi; Yutaka Furukawa; Takeshi Kimura; Toru Kita; Tatsuo Ichinohe; Takayuki Ishikawa; Masataka Sasada; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 2.  Invited review: activity-induced angiogenesis.

Authors:  Stuart Egginton
Journal:  Pflugers Arch       Date:  2008-08-13       Impact factor: 3.657

3.  Clinical and genetic correlates of circulating angiopoietin-2 and soluble Tie-2 in the community.

Authors:  Wolfgang Lieb; Justin P Zachariah; Vanessa Xanthakis; Radwan Safa; Ming-Huei Chen; Lisa M Sullivan; Martin G Larson; Holly M Smith; Qiong Yang; Gary F Mitchell; Joseph A Vita; Douglas B Sawyer; Ramachandran S Vasan
Journal:  Circ Cardiovasc Genet       Date:  2010-03-26

4.  Relevance of angiopoietin-2 and soluble P-selectin levels in patients with pulmonary arterial hypertension receiving combination therapy with oral treprostinil: a FREEDOM-C2 biomarker substudy.

Authors:  Manuel J Richter; Ralph Schermuly; Werner Seeger; Youlan Rao; Hossein A Ghofrani; Henning Gall
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

5.  Minimally invasive colorectal resection for cancer is associated with a short-lived decrease in soluble Tie-2 receptor levels, which may transiently inhibit VEGF-mediated angiogenesis (via altered blood levels of free Ang-1 and Ang-2).

Authors:  H M C Shantha Kumara; Michael J Grieco; Xiaohong Yan; Matthew F Kalady; Vincent DiMaggio; Donald G Kim; Neil Hyman; Daniel L Feingold; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-03-31       Impact factor: 4.584

6.  Angiopoietin-2 and outcome in patients with acute decompensated heart failure.

Authors:  Janine Pöss; Christian Ukena; Ingrid Kindermann; Peter Ehrlich; Georg Fuernau; Sebastian Ewen; Felix Mahfoud; Steffen Kriechbaum; Michael Böhm; Andreas Link
Journal:  Clin Res Cardiol       Date:  2014-11-19       Impact factor: 5.460

7.  Overexpression of angiopoietin-2 impairs myocardial angiogenesis and exacerbates cardiac fibrosis in the diabetic db/db mouse model.

Authors:  Jian-Xiong Chen; Heng Zeng; Jeff Reese; Judy L Aschner; Barbara Meyrick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-16       Impact factor: 4.733

8.  The inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo.

Authors:  K Rychli; C Kaun; P J Hohensinner; G Rega; S Pfaffenberger; E Vyskocil; J M Breuss; A Furnkranz; P Uhrin; J Zaujec; A Niessner; G Maurer; K Huber; J Wojta
Journal:  J Thromb Haemost       Date:  2009-12-17       Impact factor: 5.824

Review 9.  Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes.

Authors:  A M Isidori; M A Venneri; D Fiore
Journal:  J Endocrinol Invest       Date:  2016-06-25       Impact factor: 4.256

10.  Admission angiopoietin levels in children with septic shock.

Authors:  John S Giuliano; Patrick M Lahni; Kelli Harmon; Hector R Wong; Lesley A Doughty; Joseph A Carcillo; Basilia Zingarelli; Vikas P Sukhatme; Samir M Parikh; Derek S Wheeler
Journal:  Shock       Date:  2007-12       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.